RNA vs AVTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

RNA

51.6
AI Score
VS
RNA Wins

AVTX

48.5
AI Score

Investment Advisor Scores

RNA

52score
Recommendation
HOLD

AVTX

49score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric RNA AVTX Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -21.9% -69.3% RNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 51.6/100 48.5/100 RNA
Profit Margin -184.1% 0.0% AVTX
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

RNA 1M: +2.7% · 3M: -35.4% AVTX 1M: -29.1% · 3M: -56.2%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 39

RSI (14): 39.5 · Price: $7.96

AVTX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -25.9%), weak momentum, RSI 42

RSI (14): 42.4 · Price: $8.51

Fundamentals Snapshot

Metric RNA AVTX
Market Cap — —
Forward P/E -1.3 -3.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% -0.7%
Gross Margin -0.6% -648.2%
Operating Margin -7.5% -1619.6%
EPS -5.44 -2.26
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.